Literature DB >> 9525617

Ubiquitin is covalently attached to the p6Gag proteins of human immunodeficiency virus type 1 and simian immunodeficiency virus and to the p12Gag protein of Moloney murine leukemia virus.

D E Ott1, L V Coren, T D Copeland, B P Kane, D G Johnson, R C Sowder, Y Yoshinaka, S Oroszlan, L O Arthur, L E Henderson.   

Abstract

Host proteins are incorporated into retroviral virions during assembly and budding. We have examined three retroviruses, human immunodeficiency virus type 1 (HIV-1), simian immunodeficiency virus (SIV), and Moloney murine leukemia virus (Mo-MuLV), for the presence of ubiquitin inside each of these virions. After a protease treatment to remove exterior viral as well as contaminating cellular proteins, the proteins remaining inside the virion were analyzed. The results presented here show that all three virions incorporate ubiquitin molecules at approximately 10% of the level of Gag found in virions. In addition to free ubiquitin, covalent ubiquitin-Gag complexes were detected, isolated, and characterized from all three viruses. Our immunoblot and protein sequencing results on treated virions showed that approximately 2% of either HIV-1 or SIV p6Gag was covalently attached to a single ubiquitin molecule inside the respective virions and that approximately 2 to 5% of the p12Gag in Mo-MuLV virions was monoubiquitinated. These results show that ubiquitination of Gag is conserved among these retroviruses and occurs in the p6Gag portion of the Gag polyprotein, a region that is likely to be involved in assembly and budding.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9525617      PMCID: PMC109742     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  40 in total

1.  Cytoskeletal proteins inside human immunodeficiency virus type 1 virions.

Authors:  D E Ott; L V Coren; B P Kane; L K Busch; D G Johnson; R C Sowder; E N Chertova; L O Arthur; L E Henderson
Journal:  J Virol       Date:  1996-11       Impact factor: 5.103

2.  Redirecting the specificity of ubiquitination by modifying ubiquitin-conjugating enzymes.

Authors:  M M Gosink; R D Vierstra
Journal:  Proc Natl Acad Sci U S A       Date:  1995-09-26       Impact factor: 11.205

3.  Ubiquitin is conjugated to the cytoskeletal protein alpha-spectrin in mature erythrocytes.

Authors:  D Corsi; L Galluzzi; R Crinelli; M Magnani
Journal:  J Biol Chem       Date:  1995-04-14       Impact factor: 5.157

Review 4.  Protein degradation or regulation: Ub the judge.

Authors:  M Hochstrasser
Journal:  Cell       Date:  1996-03-22       Impact factor: 41.582

5.  Histone 2B can be modified by the attachment of ubiquitin.

Authors:  M H West; W M Bonner
Journal:  Nucleic Acids Res       Date:  1980-10-24       Impact factor: 16.971

6.  A multiubiquitin chain is confined to specific lysine in a targeted short-lived protein.

Authors:  V Chau; J W Tobias; A Bachmair; D Marriott; D J Ecker; D K Gonda; A Varshavsky
Journal:  Science       Date:  1989-03-24       Impact factor: 47.728

7.  Microvesicles are a source of contaminating cellular proteins found in purified HIV-1 preparations.

Authors:  J W Bess; R J Gorelick; W J Bosche; L E Henderson; L O Arthur
Journal:  Virology       Date:  1997-03-31       Impact factor: 3.616

8.  p6Gag is required for particle production from full-length human immunodeficiency virus type 1 molecular clones expressing protease.

Authors:  M Huang; J M Orenstein; M A Martin; E O Freed
Journal:  J Virol       Date:  1995-11       Impact factor: 5.103

9.  Cellular proteins bound to immunodeficiency viruses: implications for pathogenesis and vaccines.

Authors:  L O Arthur; J W Bess; R C Sowder; R E Benveniste; D L Mann; J C Chermann; L E Henderson
Journal:  Science       Date:  1992-12-18       Impact factor: 47.728

10.  Isopeptide linkage between nonhistone and histone 2A polypeptides of chromosomal conjugate-protein A24.

Authors:  I L Goldknopf; H Busch
Journal:  Proc Natl Acad Sci U S A       Date:  1977-03       Impact factor: 11.205

View more
  93 in total

Review 1.  Ubiquitin in retrovirus assembly: actor or bystander?

Authors:  V M Vogt
Journal:  Proc Natl Acad Sci U S A       Date:  2000-11-21       Impact factor: 11.205

Review 2.  The ubiquitin-proteasome pathway and proteasome inhibitors.

Authors:  J Myung; K B Kim; C M Crews
Journal:  Med Res Rev       Date:  2001-07       Impact factor: 12.944

3.  Structure and functional interactions of the Tsg101 UEV domain.

Authors:  Owen Pornillos; Steven L Alam; Rebecca L Rich; David G Myszka; Darrell R Davis; Wesley I Sundquist
Journal:  EMBO J       Date:  2002-05-15       Impact factor: 11.598

Review 4.  Viral late domains.

Authors:  Eric O Freed
Journal:  J Virol       Date:  2002-05       Impact factor: 5.103

5.  A PPxY motif within the VP40 protein of Ebola virus interacts physically and functionally with a ubiquitin ligase: implications for filovirus budding.

Authors:  R N Harty; M E Brown; G Wang; J Huibregtse; F P Hayes
Journal:  Proc Natl Acad Sci U S A       Date:  2000-12-05       Impact factor: 11.205

Review 6.  Emerging drug targets for antiretroviral therapy.

Authors:  Jacqueline D Reeves; Andrew J Piefer
Journal:  Drugs       Date:  2005       Impact factor: 9.546

Review 7.  Plunder and stowaways: incorporation of cellular proteins by enveloped viruses.

Authors:  Réjean Cantin; Sylvie Méthot; Michel J Tremblay
Journal:  J Virol       Date:  2005-06       Impact factor: 5.103

8.  Analysis of human immunodeficiency virus type 1 Gag ubiquitination.

Authors:  Eva Gottwein; Hans-Georg Kräusslich
Journal:  J Virol       Date:  2005-07       Impact factor: 5.103

9.  Rhabdoviruses and the cellular ubiquitin-proteasome system: a budding interaction.

Authors:  R N Harty; M E Brown; J P McGettigan; G Wang; H R Jayakar; J M Huibregtse; M A Whitt; M J Schnell
Journal:  J Virol       Date:  2001-11       Impact factor: 5.103

10.  Functional replacement of a retroviral late domain by ubiquitin fusion.

Authors:  Anjali Joshi; Utpal Munshi; Sherimay D Ablan; Kunio Nagashima; Eric O Freed
Journal:  Traffic       Date:  2008-08-09       Impact factor: 6.215

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.